The most effective drug in parkinsonism is: A. Bromocriptine B. Selegiline C. Levodopa + carbidopa D. Biperiden

The most effective drug in parkinsonism is:
A. Bromocriptine
B. Selegiline
C. Levodopa + carbidopa
D. Biperiden
by

1 Answer

Answer :

C. Levodopa + carbidopa
by

Related questions

The following drug is effective in chlorpromazine induced parkinsonism: A. Trihexyphenidyl B. Selegiline C. Bromocriptine D. Levodopa + carbidopa

Description : The following drug is effective in chlorpromazine induced parkinsonism: A. Trihexyphenidyl B. Selegiline C. Bromocriptine D. Levodopa + carbidopa

Last Answer : A. Trihexyphenidyl

For majority of patients of parkinsonism the standard drug therapy is: A. Levodopa B. Levodopa + carbidopa C. Levodopa + trihexiphenidyl D. Bromocriptine

Description : For majority of patients of parkinsonism the standard drug therapy is: A. Levodopa B. Levodopa + carbidopa C. Levodopa + trihexiphenidyl D. Bromocriptine

Last Answer : B. Levodopa + carbidopa

The antiparkinsonian drug which acts by inhibiting the degradation of dopamine in the brain is: A. Carbidopa B. Amantadine C. Selegiline D. Bromocriptine

Description : The antiparkinsonian drug which acts by inhibiting the degradation of dopamine in the brain is: A. Carbidopa B. Amantadine C. Selegiline D. Bromocriptine

Last Answer : C. Selegiline

The following drug is added to levodopa therapy of parkinsonism to attenuate ‘wearing off’ effect: A. Selegiline B. Trihexiphenidyl C. Amantadine D. Any of the abov

Description : The following drug is added to levodopa therapy of parkinsonism to attenuate ‘wearing off’ effect: A. Selegiline B. Trihexiphenidyl C. Amantadine D. Any of the abov

Last Answer : A. Selegiline

The following drug combination should not be used in parkinsonism: A. Levodopa + anticholinergics B. Levodopa + amantadine C. Bromocriptine + levodopa D. Amantadine + anticholinergics

Description : The following drug combination should not be used in parkinsonism: A. Levodopa + anticholinergics B. Levodopa + amantadine C. Bromocriptine + levodopa D. Amantadine + anticholinergics

Last Answer : D. Amantadine + anticholinergics

Though bromocriptine acts directly on dopamine receptors, it is used in parkinsonism only as a supplement to levodopa because: A. It has low efficacy B. It produces marked dyskinesias C. Used alone, its effective doses produce intolerable side effects D. Its therapeutic effect takes long time to develop

Description : Though bromocriptine acts directly on dopamine receptors, it is used in parkinsonism only as a supplement to levodopa because: A. It has low efficacy B. It produces marked dyskinesias C. ... its effective doses produce intolerable side effects D. Its therapeutic effect takes long time to develop

Last Answer : C. Used alone, its effective doses produce intolerable side effect

Tolerance to the antiparkinsonian action develops most rapidly in the case of: A. Levodopa B. Levodopa + carbidopa C. Amantadine D. Bromocriptine

Description : Tolerance to the antiparkinsonian action develops most rapidly in the case of: A. Levodopa B. Levodopa + carbidopa C. Amantadine D. Bromocriptine

Last Answer : C. Amantadine

The primary action by which entacapone and tolcapone enhance the therapeutic effect of levodopa-carbidopa in parkinsonism is: A. Inhibition of levodopa methylation in the liver B. Inhibition of dopamine methylation in the brain C. Inhibition of oxidative deamination of dopamine in the brain D. Facilitation of active transport of levodopa across brain capillaries

Description : The primary action by which entacapone and tolcapone enhance the therapeutic effect of levodopa-carbidopa in parkinsonism is: A. Inhibition of levodopa methylation in the liver B. Inhibition of ... of dopamine in the brain D. Facilitation of active transport of levodopa across brain capillaries

Last Answer : A. Inhibition of levodopa methylation in the liver

Use of carbidopa along with levodopa in the treatment of parkinsonism: A. Inhibits development of involuntary movements B. Minimises ‘on-off ’ effect’ C. Inhibits occurrence of behavioral abnormalities D. Accentuates nausea and vomiting

Description : Use of carbidopa along with levodopa in the treatment of parkinsonism: A. Inhibits development of involuntary movements B. Minimises ‘on-off ’ effect’ C. Inhibits occurrence of behavioral abnormalities D. Accentuates nausea and vomiting

Last Answer : B. Minimises ‘on-off ’ effect

The following is true of selegiline: A. It does not exert antiparkinsonian action unless combined with levodopa B. It overcomes the ‘on-off ’ effect in levodopa treated advanced parkinsonian patients C. It retards the progression of Parkinson's disease D. At doses used in parkinsonism it does not interfere with peripheral metabolism of dietary amines

Description : The following is true of selegiline: A. It does not exert antiparkinsonian action unless combined with levodopa B. It overcomes the on-off ' effect in levodopa treated advanced parkinsonian ... D. At doses used in parkinsonism it does not interfere with peripheral metabolism of dietary amines

Last Answer : . At doses used in parkinsonism it does not interfere with peripheral metabolism of dietary amines

Ropinirole differs from bromocriptine in the following respect: A. It does not directly activate dopamine D2 receptors B. It produces milder gastrointestinal side effects C. In early cases of parkinsonism, it is less likely to need levodopa supplementation D. Both 'B' and 'C' are correct

Description : Ropinirole differs from bromocriptine in the following respect: A. It does not directly activate dopamine D2 receptors B. It produces milder gastrointestinal side effects C. In early cases of parkinsonism, it is less likely to need levodopa supplementation D. Both 'B' and 'C' are correct

Last Answer : D. Both 'B' and 'C' are correct

In the treatment of parkinsonism, bromocriptine differs from levodopa in the following respects except: A. It does not need conversion to an active metabolite B. It has a longer duration of action C. It activates dopamine D2 receptors, with little/antagonistic action on D1 receptors D. It does not produce behavioral/psychiatric side effect

Description : In the treatment of parkinsonism, bromocriptine differs from levodopa in the following respects except: A. It does not need conversion to an active metabolite B. It has a longer duration of ... with little/antagonistic action on D1 receptors D. It does not produce behavioral/psychiatric side effect

Last Answer : D. It does not produce behavioral/psychiatric side effects

The drug which abolishes the therapeutic effect of levodopa in parkinsonism, but not that of levodopacarbidopa combination is: A. Metoclopramide B. Pyridoxine C. Chlorpromazine D. Isoniazid

Description : The drug which abolishes the therapeutic effect of levodopa in parkinsonism, but not that of levodopacarbidopa combination is: A. Metoclopramide B. Pyridoxine C. Chlorpromazine D. Isoniazid

Last Answer : B. Pyridoxine

The following adverse effect of levodopa is not minimised by combining it with carbidopa: A. Involuntary movements B. Nausea and vomiting C. Cardiac arrhythmia D. ‘On-off ’ effect

Description : The following adverse effect of levodopa is not minimised by combining it with carbidopa: A. Involuntary movements B. Nausea and vomiting C. Cardiac arrhythmia D. ‘On-off ’ effect

Last Answer : A. Involuntary movements

Which of the following drugs has mild antiparkinsonian action of its own, prolongs levodopa action and allows reduction of its dose by about 25%: A. Benserazide B. Selegiline C. Amantadine D. Pyridoxine

Description : Which of the following drugs has mild antiparkinsonian action of its own, prolongs levodopa action and allows reduction of its dose by about 25%: A. Benserazide B. Selegiline C. Amantadine D. Pyridoxine

Last Answer : B. Selegiline

Gynaecomastia can occur as a side effect of: A. Bromocriptine B. Cimetidine C. Famotidine D. Levodopa

Description : Gynaecomastia can occur as a side effect of: A. Bromocriptine B. Cimetidine C. Famotidine D. Levodopa

Last Answer : B. Cimetidine

The following is true about entacapone except: A. It acts by inhibiting degradation of dopamine in the brain B. If prolongs the therapeutic effect of levodopacarbidopa in parkinsonism C. It can accentuate levodopa induced dyskinesias D. It can cause diarrhoea as a side effec

Description : The following is true about entacapone except: A. It acts by inhibiting degradation of dopamine in the brain B. If prolongs the therapeutic effect of levodopacarbidopa in parkinsonism C. It can accentuate levodopa induced dyskinesias D. It can cause diarrhoea as a side effec

Last Answer : A. It acts by inhibiting degradation of dopamine in the brain

The antiparkinsonian action of central anticholinergics has the following features except: A. They control tremor more than rigidity B. They produce a low ceiling therapeutic effect C. They are effective in neuroleptic drug induced parkinsonism D. They are the preferred drugs in advanced case

Description : The antiparkinsonian action of central anticholinergics has the following features except: A. They control tremor more than rigidity B. They produce a low ceiling therapeutic effect C. They are effective in neuroleptic drug induced parkinsonism D. They are the preferred drugs in advanced case

Last Answer : D. They are the preferred drugs in advanced cases

Choose the correct statement about topotecan: A. It is a DNA topoisomerase I inhibitor which causes single strand DNA breaks B. It is a cell cycle specific anticancer drug C. It is a COMT-inhibitor used in advanced parkinsonism D. Both 'A' and 'B' are correc

Description : Choose the correct statement about topotecan: A. It is a DNA topoisomerase I inhibitor which causes single strand DNA breaks B. It is a cell cycle specific anticancer drug C. It is a COMT-inhibitor used in advanced parkinsonism D. Both 'A' and 'B' are correc

Last Answer : D. Both 'A' and 'B' are correct

The extrapyramidal adverse effect of antipsychotic drug therapy which does not respond to central anticholinergics is: A. Parkinsonism B. Acute muscle dystonia C. Rabbit syndrome D. Tardive dyskinesia

Description : The extrapyramidal adverse effect of antipsychotic drug therapy which does not respond to central anticholinergics is: A. Parkinsonism B. Acute muscle dystonia C. Rabbit syndrome D. Tardive dyskinesia

Last Answer : D. Tardive dyskinesia

Choose the correct statement about lamotrigine: A. It is a dopaminergic agonist used in parkinsonism B. It acts by blocking NMDA-type of glutamate receptors C. It is a broad spectrum antiepileptic drug D. It suppresses tonic-clonic seizures, but worsens absence seizures

Description : Choose the correct statement about lamotrigine: A. It is a dopaminergic agonist used in parkinsonism B. It acts by blocking NMDA-type of glutamate receptors C. It is a broad spectrum antiepileptic drug D. It suppresses tonic-clonic seizures, but worsens absence seizures

Last Answer : C. It is a broad spectrum antiepileptic drug

The following drug/drugs does/do not produce any overt CNS effect in normal individuals but exert(s) clear cut therapeutic effect at the same dose in the presence of a specific neurological/psychiatric disorder: A. Chlorpromazine B. Levodopa C. Imipramine D. All of the above

Description : The following drug/drugs does/do not produce any overt CNS effect in normal individuals but exert(s) clear cut therapeutic effect at the same dose in the presence of a specific neurological/psychiatric disorder: A. Chlorpromazine B. Levodopa C. Imipramine D. All of the above

Last Answer : B. Levodopa

Monitoring plasma drug concentration is useful while using: A. Antihypertensive drugs B. Levodopa C. Lithium carbonate D. MAO inhibitors

Description : Monitoring plasma drug concentration is useful while using: A. Antihypertensive drugs B. Levodopa C. Lithium carbonate D. MAO inhibitors

Last Answer : C. Lithium carbonate

The following is a reversible and selective MAO-A inhibitor: A. Bupropion B. Entacapone C. Moclobemide D. Selegiline

Description : The following is a reversible and selective MAO-A inhibitor: A. Bupropion B. Entacapone C. Moclobemide D. Selegiline

Last Answer : C. Moclobemide

Which of the following MAO inhibitors is most likely to produce cheese reaction: A. Tranylcypromine B. Moclobemide C. Selegiline D. Clorgyline

Description : Which of the following MAO inhibitors is most likely to produce cheese reaction: A. Tranylcypromine B. Moclobemide C. Selegiline D. Clorgyline

Last Answer : A. Tranylcypromine

Which of the following is a selective MAO-B inhibitor: A. Selegiline B. Clorgyline C. Moclobemide D. Tranylcypromine

Description : Which of the following is a selective MAO-B inhibitor: A. Selegiline B. Clorgyline C. Moclobemide D. Tranylcypromine

Last Answer : A. Selegiline

The most dependable emetic used to expel ingested poisons is: A. Intramuscular emetine B. Oral syrup ipecacuanha C. Intramuscular apomorphine D. Oral bromocriptine

Description : The most dependable emetic used to expel ingested poisons is: A. Intramuscular emetine B. Oral syrup ipecacuanha C. Intramuscular apomorphine D. Oral bromocriptine

Last Answer : C. Intramuscular apomorphine

The dopamine D2 receptor has the following feature: A. It is excitatory in nature B. It is negatively coupled to adenyl cyclase C. It is selectively blocked by bromocriptine D. It is not blocked by metoclopramide

Description : The dopamine D2 receptor has the following feature: A. It is excitatory in nature B. It is negatively coupled to adenyl cyclase C. It is selectively blocked by bromocriptine D. It is not blocked by metoclopramide

Last Answer : B. It is negatively coupled to adenyl cyclase

16.13 Gynaecomastia can be treated with: A. Chlorpromazine B. Cimetidine C. Bromocriptine D. Metoclopramide

Description : 16.13 Gynaecomastia can be treated with: A. Chlorpromazine B. Cimetidine C. Bromocriptine D. Metoclopramide

Last Answer : C. Bromocriptine

6.12 The most prominent action of bromocriptine is: A. Dopamine D2 agonism B. Dopamine D2 antagonism C. Dopamine D1 antagonism D. α adrenergic antagonism

Description : 6.12 The most prominent action of bromocriptine is: A. Dopamine D2 agonism B. Dopamine D2 antagonism C. Dopamine D1 antagonism D. α adrenergic antagonism

Last Answer : A. Dopamine D2 agonism

16.11 Bromocriptine causes the following: A. Prolactin release B. Vomiting C. Uterine contraction D. Impotence

Description : 16.11 Bromocriptine causes the following: A. Prolactin release B. Vomiting C. Uterine contraction D. Impotence

Last Answer : B. Vomiting

16.8 Drugs that suppress growth hormone release in acromegaly include the following except: A. Bromocriptine B. Somatostatin C. Octreotide D. Nafarelin

Description : 16.8 Drugs that suppress growth hormone release in acromegaly include the following except: A. Bromocriptine B. Somatostatin C. Octreotide D. Nafarelin

Last Answer : D. Nafarelin

Select the ergot compound which is primarily used for dementia: A. Bromocriptine B. Ergotamine C. Codergocrine D. Methysergide

Description : Select the ergot compound which is primarily used for dementia: A. Bromocriptine B. Ergotamine C. Codergocrine D. Methysergide

Last Answer : C. Codergocrine

Prolonged lithium therapy can cause: A. Diabetes mellitus B. Goiter C. Parkinsonism D. Gout

Description : Prolonged lithium therapy can cause: A. Diabetes mellitus B. Goiter C. Parkinsonism D. Gout

Last Answer : B. Goiter

The following side effect of typical neuroleptics may respond to propranolol: A. Parkinsonism B. Acute muscle dystonia C. Tardive dyskinesia D. Akathisia (p. 397) 30.15 3 0 . 1 5 B 30.16 3 0 . 1 6 D

Description : The following side effect of typical neuroleptics may respond to propranolol: A. Parkinsonism B. Acute muscle dystonia C. Tardive dyskinesia D. Akathisia (p. 397) 30.15 3 0 . 1 5 B 30.16 3 0 . 1 6 D

Last Answer : D. Akathisia (p. 397)

Which antiemetic selectively blocks levodopa induced vomiting without blocking its antiparkinsonian action: A. Metoclopramide B. Cisapride C. Domperidone D. Ondansetron

Description : Which antiemetic selectively blocks levodopa induced vomiting without blocking its antiparkinsonian action: A. Metoclopramide B. Cisapride C. Domperidone D. Ondansetron

Last Answer : C. Domperidone

Entacapone differs from tolcapone in the following respect/respects: A. It is shorter acting B. It acts only by inhibiting peripheral metabolism of levodopa C. It is not hepatotoxic D. All of the above are correct

Description : Entacapone differs from tolcapone in the following respect/respects: A. It is shorter acting B. It acts only by inhibiting peripheral metabolism of levodopa C. It is not hepatotoxic D. All of the above are correct

Last Answer : D. All of the above are correct

Which of the following adverse effects of levodopa has a delayed onset and increases in severity with continued therapy: A. Nausea and vomiting B. Postural hypotension C. Cardiac arrhythmia D. Abnormal movements

Description : Which of the following adverse effects of levodopa has a delayed onset and increases in severity with continued therapy: A. Nausea and vomiting B. Postural hypotension C. Cardiac arrhythmia D. Abnormal movements

Last Answer : D. Abnormal movements

Loss or alteration of taste sensation can occur a side effect of: A. Levodopa B. Captopril C. Penicillamine D. All of the above

Description : Loss or alteration of taste sensation can occur a side effect of: A. Levodopa B. Captopril C. Penicillamine D. All of the above

Last Answer : D. All of the above

The usual cardiovascular effect of levodopa is: A. Bradycardia due to increased vagal tone B. Rise in blood pressure due to increased noradrenaline content of adrenergic nerve endings C. Fall in blood pressure due to decrease in sympathetic tone D. Both ‘A’ and ‘B’ are correct

Description : The usual cardiovascular effect of levodopa is: A. Bradycardia due to increased vagal tone B. Rise in blood pressure due to increased noradrenaline content of adrenergic nerve endings C. Fall in blood pressure due to decrease in sympathetic tone D. Both ‘A’ and ‘B’ are correct

Last Answer : C. Fall in blood pressure due to decrease in sympathetic tone

In parkinsonian patients levodopa exerts the following effects except: A. Reduces skeletal muscle contractility B. Decreases muscle tone C. Increases locomotor activity D. Inhibits muscle tremor

Description : In parkinsonian patients levodopa exerts the following effects except: A. Reduces skeletal muscle contractility B. Decreases muscle tone C. Increases locomotor activity D. Inhibits muscle tremor

Last Answer : A. Reduces skeletal muscle contractility

Tolerance is generally not acquired to: A. Antisecretory action of atropine B. Sedative action of chlorpromazine C. Emetic action of levodopa D. Vasodilator action of nitrates

Description : Tolerance is generally not acquired to: A. Antisecretory action of atropine B. Sedative action of chlorpromazine C. Emetic action of levodopa D. Vasodilator action of nitrates

Last Answer : A. Antisecretory action of atropine

Interaction between the following pair of drugs can be avoided by making suitable adjustments: A. Levodopa and metoclopramide B. Furosemide and indomethacin C. Tetracyclines and ferrous sulfate D. Clonidine and chlorpromazine

Description : Interaction between the following pair of drugs can be avoided by making suitable adjustments: A. Levodopa and metoclopramide B. Furosemide and indomethacin C. Tetracyclines and ferrous sulfate D. Clonidine and chlorpromazine

Last Answer : C. Tetracyclines and ferrous sulfate

Which of the following drugs acts by inhibiting an enzyme in the body: A. Atropine B. Allopurinol C. Levodopa D. Metoclopramide

Description : Which of the following drugs acts by inhibiting an enzyme in the body: A. Atropine B. Allopurinol C. Levodopa D. Metoclopramide

Last Answer : B. Allopurinol

In a comatose patient suspected of poisoning, which of the following findings would be against the drug being morphine (a) Selegiline (b) Chlorgiline (c) Moclobemide (d) Tranylcypromine

Description : In a comatose patient suspected of poisoning, which of the following findings would be against the drug being morphine (a) Selegiline (b) Chlorgiline (c) Moclobemide (d) Tranylcypromine

Last Answer : Ans: A

A patient undergoing cancer chemotherapy is vomiting frequently. A drug that might help in this situation is (a) Bromocriptine (b) Cimetidine (c) Ketanserin (d) Loratadine (e) Ondansetron

Description : A patient undergoing cancer chemotherapy is vomiting frequently. A drug that might help in this situation is (a) Bromocriptine (b) Cimetidine (c) Ketanserin (d) Loratadine (e) Ondansetron

Last Answer : Ans: E

What is true of docetaxel: A. It is used as a reserve drug for refractory breast and ovarian cancer B. It is a selective estrogen receptor modulator used for breast cancer C. It is effective only in estrogen receptor positive breast cancer D. Both 'B' and 'C' are correct

Description : What is true of docetaxel: A. It is used as a reserve drug for refractory breast and ovarian cancer B. It is a selective estrogen receptor modulator used for breast cancer C. It is effective only in estrogen receptor positive breast cancer D. Both 'B' and 'C' are correct

Last Answer : A. It is used as a reserve drug for refractory breast and ovarian cancer

What is true of ivermectin: A. It is the most effective drug for strongyloidosis B. It is the drug of choice for onchocerciasis C. It can be used to treat pediculosis D. All of the above

Description : What is true of ivermectin: A. It is the most effective drug for strongyloidosis B. It is the drug of choice for onchocerciasis C. It can be used to treat pediculosis D. All of the above

Last Answer : D. All of the above

Drug/drugs effective in filariasis include: A. Ivermectin B. Albendazole C. Diethyl carbamazine citrate D. All of the above

Description : Drug/drugs effective in filariasis include: A. Ivermectin B. Albendazole C. Diethyl carbamazine citrate D. All of the above

Last Answer : D. All of the above